Last reviewed · How we verify
Cell therapy with bispecific antibodies
Bispecific antibodies redirect immune cells to recognize and eliminate cancer cells by simultaneously binding to tumor-associated antigens and immune cell receptors.
Bispecific antibodies redirect immune cells to recognize and eliminate cancer cells by simultaneously binding to tumor-associated antigens and immune cell receptors. Used for Hematologic malignancies (phase 2 investigational).
At a glance
| Generic name | Cell therapy with bispecific antibodies |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This cell therapy approach uses engineered bispecific antibodies that bridge cancer cells and T cells or other immune effectors, bringing them into close proximity to trigger cytotoxic killing. By targeting two distinct antigens—one on the tumor and one on the immune cell—the bispecific antibodies create a dual-recognition system that enhances specificity and immune activation against malignant cells.
Approved indications
- Hematologic malignancies (phase 2 investigational)
Common side effects
- Cytokine release syndrome
- Immune activation-related toxicity
- Infusion reactions
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (PHASE1, PHASE2)
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: